2024 KSoLA consensus on secondary dyslipidemia

Cited 1 times in

Authors: Hoyoun Won ; Jae Hyun Bae ; Hyunjung Lim ; Minji Kang ; Minjoo Kim ; Sang-Hak Lee ; on behalf of the Clinical Practice Guidelines Committee, Korean Society of Lipid and Atherosclerosis (KSoLA)

MeSH: Biomarkers / blood ; Consensus* ; Dyslipidemias* / blood ; Dyslipidemias* / diagnosis ; Dyslipidemias* / drug therapy ; Dyslipidemias* / therapy ; Humans ; Hypercholesterolemia / blood ; Hypercholesterolemia / complications ; Hypercholesterolemia / diagnosis ; Hypercholesterolemia / drug therapy ; Hypertriglyceridemia / blood ; Hypertriglyceridemia / diagnosis ; Hypertriglyceridemia / therapy ; Hypolipidemic Agents* / therapeutic use ; Risk Factors ; Treatment Outcome ; Triglycerides / blood

Keywords: Diagnosis ; Drug-related side effects and adverse reactions ; Food ; Lipoproteins ; Metabolism

Abstract: Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy.

Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.